SANCTURA XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sanctura Xr, and when can generic versions of Sanctura Xr launch?
Sanctura Xr is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in SANCTURA XR is trospium chloride. There are sixteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sanctura Xr
A generic version of SANCTURA XR was approved as trospium chloride by GLENMARK PHARMS LTD on August 13th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SANCTURA XR?
- What are the global sales for SANCTURA XR?
- What is Average Wholesale Price for SANCTURA XR?
Summary for SANCTURA XR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 70 |
Clinical Trials: | 8 |
Patent Applications: | 848 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SANCTURA XR |
DailyMed Link: | SANCTURA XR at DailyMed |
![SANCTURA XR drug patent expirations Drug patent expirations by year for SANCTURA XR](/p/graph/s/t/SANCTURA_XR-patent-expirations.png)
Recent Clinical Trials for SANCTURA XR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Neil M. Resnick | Phase 4 |
National Institute on Aging (NIA) | Phase 4 |
Karuna Pharmaceuticals | Phase 1 |
Paragraph IV (Patent) Challenges for SANCTURA XR
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SANCTURA XR | Extended-release Capsules | trospium chloride | 60 mg | 022103 | 1 | 2009-03-02 |
US Patents and Regulatory Information for SANCTURA XR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | SANCTURA XR | trospium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 022103-001 | Aug 3, 2007 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SANCTURA XR
See the table below for patents covering SANCTURA XR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2007510656 | ⤷ Sign Up | |
Australia | 2004289223 | Once daily dosage forms of trospium | ⤷ Sign Up |
Japan | 5610663 | ⤷ Sign Up | |
Denmark | 2210605 | ⤷ Sign Up | |
Portugal | 2210605 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |